- Home
- PRPH vs BLRX Comparison
PRPH vs BLRX Comparison
Compare PRPH & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRPH
- BLRX
- Stock Information
- Founded
- PRPH 1989
- BLRX 2003
- Country
- PRPH United States
- BLRX Israel
- Employees
- PRPH N/A
- BLRX N/A
- Industry
- PRPH Biotechnology: Pharmaceutical Preparations
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- PRPH Health Care
- BLRX Health Care
- Exchange
- PRPH Nasdaq
- BLRX Nasdaq
- Market Cap
- PRPH 10.7M
- BLRX 12.2M
- IPO Year
- PRPH 1997
- BLRX 2011
- Fundamental
- Price
- PRPH $0.35
- BLRX $2.94
- Analyst Decision
- PRPH
- BLRX Buy
- Analyst Count
- PRPH 0
- BLRX 2
- Target Price
- PRPH N/A
- BLRX $26.00
- AVG Volume (30 Days)
- PRPH 1.8M
- BLRX 26.6K
- Earning Date
- PRPH 03-31-2025
- BLRX 05-27-2025
- Dividend Yield
- PRPH N/A
- BLRX N/A
- EPS Growth
- PRPH N/A
- BLRX N/A
- EPS
- PRPH N/A
- BLRX N/A
- Revenue
- PRPH $6,770,000.00
- BLRX $28,940,000.00
- Revenue This Year
- PRPH N/A
- BLRX N/A
- Revenue Next Year
- PRPH $64.06
- BLRX N/A
- P/E Ratio
- PRPH N/A
- BLRX N/A
- Revenue Growth
- PRPH N/A
- BLRX 502.92
- 52 Week Low
- PRPH $0.22
- BLRX $2.85
- 52 Week High
- PRPH $7.48
- BLRX $35.60
- Technical
- Relative Strength Index (RSI)
- PRPH 41.16
- BLRX 37.85
- Support Level
- PRPH $0.35
- BLRX $3.01
- Resistance Level
- PRPH $0.52
- BLRX $3.61
- Average True Range (ATR)
- PRPH 0.09
- BLRX 0.21
- MACD
- PRPH -0.00
- BLRX 0.01
- Stochastic Oscillator
- PRPH 12.41
- BLRX 11.84
About PRPH ProPhase Labs Inc. (DE)
ProPhase Labs Inc is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers and government organizations. The Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.